Erratum: Context Dependent Effects of Chimeric Peptide Morpholino Conjugates Contribute to Dystrophin Exon-skipping Efficiency (Context Dependent Effects of Chimeric Peptide Morpholino Conjugates Contribute to Dystrophin Exon-skipping Efficiency (2013) 2 (1–10), (S2162253116301834), (10.1038/mtna.2013.51));Context dependent effects of chimeric peptide morpholino conjugates contribute to dystrophin exon-skipping efficiency

Molecular Therapy Nucleic Acids

Volumn 2, Issue SEP, 2013, Pages e124-

  Yin, HaiFang ^a,b   Boisguerin, Prisca ^c   Moulton, Hong M ^d   Betts, Corinne ^b   Seow, Yiqi ^b   Boutilier, Jordan ^e   Wang, Qingsong ^a   Walsh, Anthony ^b   Lebleu, Bernard ^c   Wood, Matthew J A ^b  

^a TIANJIN MEDICAL UNIVERSITY   (China)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c UNIVERSITÉ DE MONTPELLIER   (France)

^d OREGON STATE UNIVERSITY   (United States)

^e SIGA Technologies Incorporated   (United States)

Author keywords

Antisense oligonucleotide; Chimeric peptide conjugate; Duchenne muscular dystrophy; Exon skipping

Indexed keywords

CELL PENETRATING PEPTIDE; DYSTROPHIN; MORPHOLINO OLIGONUCLEOTIDE; PEPTIDE; PEPTIDE 3; PEPTIDE 9; PROTEOHEPARAN SULFATE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CELL TRANSPORT; CONTROLLED STUDY; DUCHENNE MUSCULAR DYSTROPHY; EXON SKIPPING; FEMALE; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; INTERNALIZATION; MOUSE; MUSCLE CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN MOTIF; PROTEIN PROTEIN INTERACTION; PROTEIN TRANSPORT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TARGET ORGAN; WESTERN BLOTTING;

EID: 84903753039     PISSN: None     EISSN: 21622531     Source Type: Journal    
DOI: 10.1016/j.omtn.2020.08.026     Document Type: Erratum

References (27)

1. Wood, MJ, Gait, MJ and Yin, H (2010). RNA-targeted splice-correction therapy for neuromuscular disease. Brain 133(Pt 4): 957-972.
2. Lu, QL, Rabinowitz, A, Chen, YC, Yokota, T, Yin, H, Alter, J et al. (2005). Systemic delivery of antisense oligoribonucleotide restores dystrophin expression in body-wide skeletal muscles. Proc Natl Acad Sci USA 102: 198-203. (Pubitemid 40094452)
3. Alter, J, Lou, F, Rabinowitz, A, Yin, H, Rosenfeld, J, Wilton, SD et al. (2006). Systemic delivery of morpholine oligonucleotide restores dystrophin expression bodywide and improves dystrophic pathology. Nat Med 12: 175-177. (Pubitemid 43214742)
4. Yokota, T, Lu, QL, Partridge, T, Kobayashi, M, Nakamura, A, Takeda, S et al. (2009). Efficacy of systemic morpholino exon-skipping in Duchenne dystrophy dogs. Ann Neurol 65: 667-676.
5. Yin, H, Moulton, HM, Seow, Y, Boyd, C, Boutilier, J, Iverson, P et al. (2008). Cell-penetrating peptide-conjugated antisense oligonucleotides restore systemic muscle and cardiac dystrophin expression and function. Hum Mol Genet 17: 3909-3918. (Pubitemid 352762853)
6. Goemans, NM, Tulinius, M, van den Akker, JT, Burm, BE, Ekhart, PF, Heuvelmans, N et at (2011). Systemic administration of PRO051 in Duchenne's muscular dystrophy. N Engl J Med 364: 1513-1522.
7. Cirak, S, Arechavala-Gomeza, V, Guglieri, M, Feng, L, Torelli, S, Anthony, K et al. (2011). Exon skipping and dystrophin restoration in patients with Duchenne muscular dystrophy after systemic phosphorodiamidate morpholino oligomer treatment: an open-label, phase 2, dose-escalation study. Lancet 378: 595-605.
8. Yin, H, Lu, Q and Wood, M (2008). Effective exon skipping and restoration of dystrophin expression by peptide nucleic acid antisense oligonucleotides in mdx mice. Mol Ther 16: 38-45.
9. Wu, B, Lu, P, Benrashid, E, Malik, S, Ashar, J, Doran, TJ et al. (2010). Dose-dependent restoration of dystrophin expression in cardiac muscle of dystrophic mice by systemically delivered morpholino. Gene Ther 17: 132-140.
10. Wu, B, Moulton, HM, Iversen, PL, Jiang, J, Li, J, Li, J et al. (2008). Effective rescue of dystrophin improves cardiac function in dystrophin-deficient mice by a modified morpholino oligomer. Proc Natl Acad Sci USA 105: 14814-14819.
11. Jearawiriyapaisarn, N, Moulton, HM, Buckley, B, Roberts, J, Sazani, P, Fucharoen, S et al. (2008). Sustained dystrophin expression induced by peptide-conjugated morpholino oligomers in the muscles of mdx mice. Mol Ther 16: 1624-1629.
12. Wu, B, Li, Y, Morcos, PA, Doran, TJ, Lu, P and Lu, QL (2009). Octa-guanidine morpholino restores dystrophin expression in cardiac and skeletal muscles and ameliorates pathology in dystrophic mdx mice. Mol Ther 17: 864-871.
13. Samoylova, TI and Smith, BF (1999). Elucidation of muscle-binding peptides by phage display screening. Muscle Nerve 22: 460-466. (Pubitemid 29173543)
14. Yin, H, Moulton, HM, Betts, C, Seow, Y, Boutilier, J, Iverson, PL et al. (2009). A fusion peptide directs enhanced systemic dystrophin exon skipping and functional restoration in dystrophin-deficient mdx mice. Hum Mol Genet 18: 4405-4414.
15. Yin, H, Moulton, HM, Betts, C, Merritt, T, Seow, Y, Ashraf, S et al. (2010). Functional rescue of dystrophin-deficient mdx mice by a chimeric peptide-PMO. Mol Ther 18: 1822-1829.
16. Seow, Y, Yin, H and Wood, MJ (2010). Identification of a novel muscle targeting peptide in mdx mice. Peptides 31: 1873-1877.
17. Yin, H, Saleh, AF, Betts, C, Camelliti, P, Seow, Y, Ashraf, S et al. (2011). Pip5 transduction peptides direct high efficiency oligonucleotide- mediated dystrophin exon skipping in heart and phenotypic correction in mdx mice. Mol Ther 19: 1295-1303.
18. Guterstam, P, Madani, F, Hirose, H, Takeuchi, T, Futaki, S, El Andaloussi, S et al. (2009). Elucidating cell-penetrating peptide mechanisms of action for membrane interaction, cellular uptake, and translocation utilizing the hydrophobic counter-anion pyrenebutyrate. Biochim Biophys Acta 1788: 2509-2517.
19. Turnbull, J, Powell, A and Guimond, S (2001). Heparan sulfate: decoding a dynamic multifunctional cell regulator. Trends Cell Biol 11: 75-82. (Pubitemid 32144754)
20. Lebleu, B, Moulton, HM, Abes, R, Ivanova, GD, Abes, S, Stein, DA et al. (2008). Cell penetrating peptide conjugates of steric block oligonucleotides. Adv Drug Deliv Rev 60: 517-529. (Pubitemid 351217082)
21. Sadoshima, J and Izumo, S (1993). Molecular characterization of angiotensin II-induced hypertrophy of cardiac myocytes and hyperplasia of cardiac fibroblasts. Critical role of the AT1 receptor subtype. Circ Res 73: 413-423. (Pubitemid 23238726)
22. Melikov, K and Chernomordik, LV (2005). Arginine-rich cell penetrating peptides: from endosomal uptake to nuclear delivery. Cell Mol Lite Sci 62: 2739-2749. (Pubitemid 41779944)
23. Richard, JP, Melikov, K, Brooks, H, Prevot, P, Lebleu, B and Chernomordik, LV (2005). Cellular uptake of unconjugated TAT peptide involves clathrin-dependent endocytosis and heparan sulfate receptors. J Biol Chem 280: 15300-15306. (Pubitemid 40562886)
24. Ziegler, A, Nervi, P, Dürrenberger, M and Seelig, J (2005). The cationic cell-penetrating peptide CPP(TAT) derived from the HIV-1 protein TAT is rapidly transported into living fibroblasts: optical, biophysical, and metabolic evidence. Biochemistry 44: 138-148. (Pubitemid 40095715)
25. Console, S, Marty, C, García-Echeverría, C, Schwendener, R and Ballmer-Hofer, K (2003). Antennapedia and HIV transactivator of transcription (TAT) "protein transduction domains" promote endocytosis of high molecular weight cargo upon binding to cell surface glycosaminoglycans. J Biol Chem 278: 35109-35114. (Pubitemid 37102274)
26. Mae, M, Andaloussi, SE, Lehto, T and Langel, U (2009). Chemically modified cell-penetrating peptides for the delivery of nucleic acids. Expert Opin Drug Deliv 6: 1195-1205.
27. Wu, RP, Youngblood, DS, Hassinger, JN, Lovejoy, CE, Nelson, MH, Iversen, PL et al. (2007). Cell-penetrating peptides as transporters for morpholino oligomers: effects of amino acid composition on intracellular delivery and cytotoxicity. Nucleic Acids Res 35: 5182-5191. (Pubitemid 47394201)